Kindeva announces leadership transition to drive strategic growth
Minnesota, USA-based contract development and manufacturing organization (CDMO) and drug delivery innovator Kindeva today announced a series of planned leadership transitions designed to position the company for accelerating growth in its core businesses focused on parenteral and inhaled drug delivery.
Effective January 1, 2026, David Stevens, most recently president at Kindeva, has assumed the role of chief executive for the company. With a proven track record of successfully building and leading teams through significant growth and capacity expansion, his appointment will ensure Kindeva continues to advance innovation and customer partnerships that improve patient outcomes.
As part of this transition, Milton Boyer has stepped down from his role as chief executive. Mr Boyer will continue to serve as an independent member of the Board of Directors, providing strategic guidance and continuity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze